期刊文献+

RNA干扰ERCC1基因表达对肺腺癌细胞A549/DDP顺铂耐药的影响 被引量:11

Enhanced Cisplatin Cytotoxicity by RNA Interfering the Excision Repair Cross-complementing Gene 1 in Lung Cancer Cell A549/DDP
在线阅读 下载PDF
导出
摘要 背景与目的核苷酸切除修复机制可修复顺铂(DDP)造成的DNA损伤,作为其中的关键酶之一,切除修复交叉互补基因1(excision repair cross-complementing gene1,ERCC1)的表达可能与DDP耐药有关。本研究旨在探讨小干扰RNA沉默ERCC1基因表达对肺腺癌耐药细胞A549/DDP药物敏感性的影响。方法将体外设计合成针对ERCC1的小分子RNA(siRNA)转染A549/DDP细胞,RT-PCR检测ERCC1 mRNA水平;Western blot检测ERCC1蛋白表达的变化;MTT检测RNA干扰后细胞药物敏感性改变。结果 ERCC1 RNAi干扰后ERCC1 mRNA表达指数降低,明显低于对照组,干扰后ERCC1 mRNA表达抑制率为90.4%。转染ERCC1 siRNA降低了ERCC1蛋白的表达水平。MTT显示分别用2μg/mL、4μg/mL、8μg/mL、16μg/mL、32μg/mL顺铂处理细胞48h,转染ERCC1 siRNA细胞组较对照组敏感性明显增高,干扰前A549/DDP细胞IC50为12.49μg/mL,干扰后A549/DDP细胞IC50下降为9.27μg/mL。结论 ERCC1 siRNA干扰可以降低ERCC1的表达水平,并可提高A549/DDP细胞对顺铂的敏感性。 Background and objective The excision repair cross-complementing gene 1(ERCC1),which is important in the repair of cisplatin-DNA adducts,was reported to be related to cisplatin resistance in tumor cells.The aim of this study is to investigate the changes of cisplatin sensitivity by silencing ERCC1 gene in lung cancer cell.Methods The small interfering RNA(siRNA) targeting ERCC1 gene was designed and synthesized,and transfected to lung cancer cell A549/DDP.The mRNA and protein expression levels of ERCC1 were evaluated by RT-PCR and Western blot.The changes of cisplatin sensitivity after RNA interference were examined by methyl thiazolyl assay.Results In A549/DDP cell,the mRNA and protein levels of ERCC1 were decreased and the sensitivity to cisplatin was increased from 12.49 μg/mL to 9.27 μg/mL after transfection.Conclusion The sensitivity to cisplatin of lung cancer cell A549/DDP could be enhanced by RNA interfering ERCC1 gene targeted code 346.
出处 《中国肺癌杂志》 CAS 2010年第9期846-849,共4页 Chinese Journal of Lung Cancer
基金 浙江省医药卫生优秀青年科技人才专项基金(No.2004QN004)资助~~
关键词 ERCC1基因 RNA干扰 顺铂 肺肿瘤 ERCC1 gene RNAi Cisplatin Lung neoplasms
  • 相关文献

参考文献1

二级参考文献10

  • 1魏嘉,刘宝瑞,王亚平,钱晓萍.DNA修复基因单核苷酸多态性与铂类药物抵抗研究进展[J].中华肿瘤杂志,2006,28(3):161-163. 被引量:31
  • 2毛友生,高燕宁,赫捷,张德超,程书钧.肺癌分子生物学特性与转移和预后的关系[J].中华肿瘤杂志,2006,28(8):632-634. 被引量:60
  • 3Rosell R, Cecere F, Santarpia M, et al. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol, 2006, 6 : 323-331.
  • 4Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 2006, 355:983-991.
  • 5Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med, 2004, 350:351-360.
  • 6Zhu XD, Niedemhofer L, Kuster B, et al. ERCC1/XPF removes the 3' overhang fromuneapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes. Mol Cell, 2003, 12:1489-1498.
  • 7Takenaka T, Yoshino I, Kouso H, et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer, 2007, 121:895-900.
  • 8Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res, 2002, 8:2286-2291.
  • 9Azuma K, Komohara Y, Sasada T, et al. Excision repair crosscomplementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci, 2007, 98 : 1336-1343.
  • 10Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol, 2006, 17 : 1818-1825.

共引文献9

同被引文献244

引证文献11

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部